FGF-23 levels increase as CKD progresses, leading to a “trade-off mechanism” between normalizing serum phosphate concentrations and activation of 1,25(OH)2D, which may cause severe SHP [26]. This evidence concerns the gene FGF23 and chronic kidney disease.